Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Potential Role of Targeting KDR and Proteasome Inhibitors in the Therapy of Esophageal Squamous Cell Carcinoma.

Technology in cancer research & treatment - 1 Jan 2000

Zhang Ling, Niu Xia, Bi Yanghui, Cui Heyang, Li Hongyi, Cheng Xiaolong

Abstract excerpt

Esophageal squamous cell carcinoma (ESCC) is one of the most aggressive cancer types in China. In recent years, progress has been made in various types of cancer genomics including ESCC. However, the clinical significance of genomic variation of ESCC remains poorly defined. In the present study, genomic sequencing data from 469 ESCC cases were analyzed and potential therapeutic targets in the Druggable Genome...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Databases, Genetic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Esophageal Squamous Cell Carcinoma

Share to Gene Knockdown Techniques

Share to Molecular Targeted Therapy

Share to Proteasome Inhibitors

Share to Vascular Endothelial Growth Factor Receptor-2

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 32924793
DOI: 10.1177/1533033820948060
PMCID: PMC7493273

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Potential Role of Targeting KDR and Proteasome Inhibitors in the Therapy of Esophageal Squamous Cell Carcinoma.PMID 32924793Read ↗

Leveraging single-cell and multi-omics approaches to identify MTOR-centered deubiquitination signatures in esophageal cancer therapy.Semantic proximity Read ↗

Six Novel Biomarkers for Diagnosis and Prognosis of Esophageal squamous cell carcinoma: validated by scRNA-seq and qPCRSemantic proximity Read ↗

Identification of predictors of drug sensitivity using patient-derived models of esophageal squamous cell carcinomaSemantic proximity Read ↗

Identification of hub genes and therapeutic drugs in esophageal squamous cell carcinoma based on integrated bioinformatics strategySemantic proximity Read ↗

Personalized targeted therapy for esophageal squamous cell carcinoma.Semantic proximity Read ↗

Identification of 2 Ubiquitin-Proteasome System-Related Subtypes in Esophageal Squamous Cell Carcinoma for Prognostic and Immunotherapeutic Response Prediction.Semantic proximity Read ↗

Genetic Alterations of Esophageal Squamous Cell Carcinoma in Korean PatientsSemantic proximity Read ↗

A Comprehensive Analysis of Alterations in DNA Damage Repair Pathways Reveals a Potential Way to Enhance the Radio-Sensitivity of Esophageal Squamous Cell CancerSemantic proximity Read ↗

Comprehensive genomic analysis of Oesophageal Squamous Cell Carcinoma reveals clinical relevance.Semantic proximity Read ↗

NEK2 Promotes the Migration, Invasion, Proliferation and Drug Resistance of ESCC Through the E2F1-IGF2 PathwaySemantic proximity Read ↗

Identification of the key transcription factors in esophageal squamous cell carcinomaSemantic proximity Read ↗

Identifying key mutations of radioresponsive genes in esophageal squamous cell carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.